GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Forward PE Ratio

GENinCode (LSE:GENI) Forward PE Ratio : 0.00 (As of May. 03, 2025)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Forward PE Ratio?

GENinCode's Forward PE Ratio for today is 0.00.

GENinCode's PE Ratio without NRI for today is 0.00.

GENinCode's PE Ratio (TTM) for today is 0.00.


GENinCode Forward PE Ratio Historical Data

The historical data trend for GENinCode's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Forward PE Ratio Chart

GENinCode Annual Data
Trend
Forward PE Ratio

GENinCode Semi-Annual Data
Forward PE Ratio

Competitive Comparison of GENinCode's Forward PE Ratio

For the Diagnostics & Research subindustry, GENinCode's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GENinCode's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where GENinCode's Forward PE Ratio falls into.


;
;

GENinCode Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


GENinCode  (LSE:GENI) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


GENinCode Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of GENinCode's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GENinCode Business Description

Traded in Other Exchanges
N/A
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.